期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼的合成 被引量：3

Synthesis of Gefitinib
下载PDF
导出
摘要 以3-羟基-4-甲氧基苯甲醛为起始原料,经缩合,氰基化,硝化,还原,合环等七步反应制得4-(3-氯-4-氟苯胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉(吉非替尼,ZD1839),其结构经IR、1H-NMR、13C-NMR和MS确认,总收率31.81%。 The 4-（3-chloro-4-fluorophenylamino）-7-methoxy-6-[3-（4-morpholinyl）pro-poxy]quinazoline（Geifitinib,ZD1839） was synthesized from 3-hydroxy-4-methoxybenzaldehyde,through a seven-step procedure of condensation,conversion of aldehyde to nitrile,n-itration,reduction,cyclization,et al.,and the total yield reached 31.81%.The structure of the compound was characterized by IR,^1H-NMR,^13C-NMR,and MS.
作者 吕同杰 欧阳贵平 孟祥冰 刘小余
机构地区 教育部绿色农药与农业生物工程重点实验室贵州大学精细化工研究开发中心
出处 《广州化工》 CAS 2010年第12期154-156,共3页 GuangZhou Chemical Industry
关键词 药物合成 表皮生长因子受体 ZD1839 抗癌药 drug synthesis epidermal growth factor receptor（EGFR） ZD1839 anticancer drug
分类号 TQ244.1 [化学工程—有机化工]
  • 相关文献

参考文献13

  • 1Frampton JE,Easthope SE.Gefitinib[J].Drugs,2004,64(21):2475-2492.
  • 2张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量：13
  • 3李付刚,陈毕峰.喹唑啉类抗癌药物的合成研究进展[J].精细与专用化学品,2010,18(2):45-54. 被引量：6
  • 4张华,赵金浩,王晖.4-(3-氯-4-氟苯胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹啉的合成法[P].CN:200810122242.2,2009-4-8.
  • 5袁立,郝金恒,张勇,王玉亚,王晖,陈皎月,宫平.4-(3-氯-4-氟苯胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的合成[J].中国药物化学杂志,2005,15(1):39-41. 被引量：8
  • 6杜鹏,潘春跃,彭东明.吉非替尼的合成工艺改进[J].中国新药杂志,2006,15(21):1849-1851. 被引量：7
  • 7Petr Knesl,Dirk R(o)seling and Ulrich Jordis.Improved Synthesis of Substiuted 6,7-Dihydroxy-4-quinazolineamines:Tandutinib,Erlotinib and Gefitinib[J].Molecules,2006,11:286-297.
  • 8Ji-Quan Wang,Mingzhang Gao elt.Synthesis of[11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase[J].Bioorganic & Medicinal Chemnistry Letters.2006,16:4102-4106.
  • 9Ming Dong Li,You Guang Zheng and Min Ji.Synthesis of Gefitinib from Methl 3-Hydroxy-4-methoxy-benzoate[J].Molecules,2007,12:673-678.
  • 10Venkateshappa Chandregowda,Gudapati Venkateswara Rao,et al.Improved Synthesis of Gefitinib and Erlotinib Hydrochloride-Aanticancer Agents[J].Taylor & Francis Group.2007,37:3409-3415.

二级参考文献43

  • 1抗癌药物:关于开发拉帕替尼的原理探讨EDB/OL].广州:中国新药网.2009-3-13.http://www.lapatini.org/Html/Article/76.html.
  • 2药物开发:口服抗肿瘤新药Erlotinib(埃洛替尼)的前药研究[DB/OL].常州:三药工程开发院.2006-9-6.http://www.sanyao.org.cn/govnews/200696/0000004053.html.
  • 3Geroni, Maria, Cristina. A morpholinyl anthracycline derivative combined with protein kinase inhibitors [P]. WO2009016072, 2009.
  • 4张华,赵金浩,王晖.4-(3-氯-4-氟苯氨基)-7-甲氧基-6-[3-(4吗啉基)-丙氧基]喹啉的合成法[P].CN200810122242.2,2009-4-8.
  • 5Barker, Andrew, John . Quinazoline derivatives[P]. EP 0566226, 1993-10-20.
  • 6Gibson, Keith, Hopkinson . Quinazoline derivatives[P]. WO 199633980, 1996-10-31.
  • 7Thomas, Andrew, Peter. Oxindole Derivatives [P] .WO 199742187,1997-11-13.
  • 8Rro, Dharmaraj, Ramachandra. Process for the preparation of Gefitinib[P]. WO 2008125867,2008-10-23.
  • 9Ji-Quan Wang, Mingzhang Gao, Kathy D. Miller. Synthesis of [^11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase[J]. Bioorganic & Medicinal Chemistry Letters,2006,16(15) :4102-4106.
  • 10朱崇泉,迟玉石,邓银来.4-(3-氯-4-氟苯基氨基)-7-甲氧基-6-(3-吗啉丙氧基)喹唑啉的制备方法[P].CN200510094005.6,2005-08-25.

共引文献32

同被引文献20

  • 1金波,陈国华,邹爱峰,石涛,任金山.吉非替尼的合成[J].中国药科大学学报,2005,36(1):92-94. 被引量：11
  • 2Mendelsohn J. Blockade of receptors for growth factors:An anticancer therapy-the fourth annual Joseph H.burchenal american association for cancer research clinical research award lecture[J].Clinical Cancer Research,2000.747-753.
  • 3Wong A J,Bigner S H,Bigner D D. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification[J].Medical Sciences,1987.6899-6903.
  • 4Khaled Abouzid,Samia Shouman. Design,synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase[J].Bioorganic and Medicinal Chemistry Letters,2008.7543-7551.
  • 5Chandregowda V,Venkateshwara Rao G,Chandrasekhara Reddy G. Convergent approach for commercial synthesis of gefitinib and erlotinib[J].Organic Process Research & Development,2007.813-816.
  • 6Chandregowda V,Venkateshwara Rao G,Chandrasekhara Reddy G. One-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones and synthesis of Gefitinib and Erlotinib hydrochloride[J].Heterocycles,2007.39-48.
  • 7AstraZeneca plc ( GB ). Oneolytic EGF receptor tyrosine kinase inhibitor IressaTM [ J ]. Drugs Future, 2002,27 ( 4 ) : 339 - 345.
  • 8Zhang H, Zhao JH, Wang H. Synthesis of 4-(3-ehloro-4-fluoro- phenylamineo ) -?-methoxy- 6-( 3-morpholin-4-yl-propoxy ) -quin- azoline: CN,200810122242.2[ P]. 2009-04-08.
  • 9Li XS, Zhang AQ, Huang L. Process for the preparation of gefitinib : CN,200910192850.5 [ P]. 2009-09-30.
  • 10Assessment report for Iressa Procedure No. EMEA/H/ C/001016[R].

引证文献3

二级引证文献9

广州化工
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部